17 Nov 08 Ferumoxytol Resubmission Designated Complete, Class 1 Response By FDA - Iron Deficiency Anemia In Chronic Kidney Disease Patients
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s resubmission to the October 2008 Complete Response letter for its New Drug Application (NDA) for ferumoxytol as a complete, Class 1 response. The FDA has established a December 30, 2008 Prescription Drug User Fee Act (PDUFA) target action date.
(more…)
Tags: Anemia, Chronic Kidney Disease, Disease Patients, Drug Application, Fda, Ferumoxytol, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Iron Anemia, Iron Deficiency, Iron Deficiency Anemia, Nasdaq, Nda, Pharmaceuticals Inc, Prescription Drug, Response Letter, Target Action
17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Lead, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
17 Nov 08 Case Of Patient "Cured" Of HIV Baffles Doctors
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been “cured” by a bone marrow transplant given to treat his acute myeloid leukemia.
(more…)
Tags: Acute Myeloid Leukemia, American Patient, Baffles, Bone Marrow, Doctors, Hiv, Hiv Infection, Leukemia, Living In Berlin
17 Nov 08 Bone Marrow Toxicity In Advanced Lung Cancer May Be Reduced By Proton Therapy And Concurrent Chemotherapy
Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
(more…)
Tags: Anderson Cancer Center, Bone Cancer, Bone Marrow Toxicity, Cancer Chemotherapy, Cancer Therapy, Cell Lung Cancer, Chemotherapy, Chemotherapy Patients, Imrt, Instances, Intensity Modulated Radiation, Lung Cancer, M D Anderson, M D Anderson Cancer Center, Non Small Cell Lung Cancer, Proton Beam Therapy, Proton Therapy, Small Cell Lung Cancer, University Of Texas, University Of Texas M D Anderson Cancer Center
17 Nov 08 ‘Femtomolar Optical Tweezers’ May Enable Sensitive Blood Tests
Cutting-edge “tweezers” are so sensitive that they can feel the tell-tale tug of tiny concentrations of pathogens in blood samples, yet don’t ever need to be sterilized - or even held - as they are ephemeral and weightless. The National Institute of Standards and Technology (NIST) has licensed a patented “optical tweezers” technique for detecting and measuring very small concentrations of a biological substance - such as a virus on a surface.
(more…)
Tags: Blood Samples, Blood Tests, Cutting Edge, National Institute Of Standards, National Institute Of Standards And Technology, National Institute Of Standards And Technology Nist, Optical Tweezers, Pathogens, Tug, Virus
17 Nov 08 Researchers Use New Method To Control Bleeding In Hemophilia
Investigators at Children’s Research Institute, BloodCenter of Wisconsin’s Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient’s own platelets. In the October 2008 edition of Blood, investigators describe how a gene-modified bone marrow transplant can be used to initiate clotting in hemophilia.
(more…)
Tags: Blood Clot, Blood Research, Bloodcenter Of Wisconsin, Bone Marrow Transplant, Clotting Factor, Control, Hemophilia, Investigators, Medical College Of Wisconsin, Platelets
17 Nov 08 Documentary Examining Deadly Blood Disorders And Lifesaving Research To Premiere On Discovery Health
Peabody-Award-winning filmmaker, Joseph Lovett, in conjunction with the American Society of Hematology (ASH) presents BLOOD DETECTIVES, an hour-long documentary airing on Discovery Health on December 19, 2008, at 7:00 p.m. ET/PT and again at 12:00 a.m. ET/PT. BLOOD DETECTIVES focuses on the medical mysteries and lifesaving work of highly specialized doctors, hematologists, as they race against time to unravel medical mysteries and save lives, from leukemia to blood clots and more.
(more…)
Tags: Ash, Blood Clots, Blood Disorders, Conjunction, Deadly Blood, Detectives, Discovery Health, Doctors, Documentary, Filmmaker, Hematology, Joseph Lovett, Leukemia, Medical Mysteries, Peabody Award, Premiere, Presents, Race Against Time
17 Nov 08 Documentary Examining Deadly Blood Disorders And Lifesaving Research To Premiere On Discovery Health
Peabody-Award-winning filmmaker, Joseph Lovett, in conjunction with the American Society of Hematology (ASH) presents BLOOD DETECTIVES, an hour-long documentary airing on Discovery Health on December 19, 2008, at 7:00 p.m. ET/PT and again at 12:00 a.m. ET/PT. BLOOD DETECTIVES focuses on the medical mysteries and lifesaving work of highly specialized doctors, hematologists, as they race against time to unravel medical mysteries and save lives, from leukemia to blood clots and more.
(more…)
17 Nov 08 New One-Stop Diabetic Rheumatology Clinic Is First In UK
Diabetes Mellitus is one of the most common chronic disorders in the population, affecting some 2 million people in the UK. Patients with diabetes (both Type 1 and 2) suffer an array of rheumatic complaints which are wide-ranging in nature and are often complex in management.
(more…)
Tags: Array, Chronic Disorders, Diabetes, Diabetes Mellitus, Diabetic, Nature, Population, Rheumatic Complaints, Uk Patients
17 Nov 08 Documentary Examining Deadly Blood Disorders And Lifesaving Research To Premiere On Discovery Health
Peabody-Award-winning filmmaker, Joseph Lovett, in conjunction with the American Society of Hematology (ASH) presents BLOOD DETECTIVES, an hour-long documentary airing on Discovery Health on December 19, 2008, at 7:00 p.m. ET/PT and again at 12:00 a.m. ET/PT. BLOOD DETECTIVES focuses on the medical mysteries and lifesaving work of highly specialized doctors, hematologists, as they race against time to unravel medical mysteries and save lives, from leukemia to blood clots and more.
(more…)
17 Nov 08 Documentary Examining Deadly Blood Disorders And Lifesaving Research To Premiere On Discovery Health
Peabody-Award-winning filmmaker, Joseph Lovett, in conjunction with the American Society of Hematology (ASH) presents BLOOD DETECTIVES, an hour-long documentary airing on Discovery Health on December 19, 2008, at 7:00 p.m. ET/PT and again at 12:00 a.m. ET/PT. BLOOD DETECTIVES focuses on the medical mysteries and lifesaving work of highly specialized doctors, hematologists, as they race against time to unravel medical mysteries and save lives, from leukemia to blood clots and more.
(more…)
Tags: Joseph Lovett, Medical Mysteries, Peabody Award
17 Nov 08 Documentary Examining Deadly Blood Disorders And Lifesaving Research To Premiere On Discovery Health
Peabody-Award-winning filmmaker, Joseph Lovett, in conjunction with the American Society of Hematology (ASH) presents BLOOD DETECTIVES, an hour-long documentary airing on Discovery Health on December 19, 2008, at 7:00 p.m. ET/PT and again at 12:00 a.m. ET/PT. BLOOD DETECTIVES focuses on the medical mysteries and lifesaving work of highly specialized doctors, hematologists, as they race against time to unravel medical mysteries and save lives, from leukemia to blood clots and more.
(more…)
17 Nov 08 INNO-406 Demonstrates Positive Clinical Responses In Phase 1 Trial In Patients With Chronic Myeloid Leukemia
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx’s potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).
(more…)
Tags: Abl, Biopharmaceutical Company, Chronic Leukemia, Chronic Myeloid Leukemia, Clinical Responses, Clinical Trial, Cml, Commercialization, Kinase Inhibitor, Leukemia, Lyn, Nasdaq, Phase 1, Today Announced That
17 Nov 08 Improved Recovery Rates And Reduced Mortality Following Dual Treatment For Stroke
It appears that stroke patients who receive both intravenous thrombolysis - a minimally invasive treatment that dissolves abnormal blood clots - and endovascular interventions - such as drugs and implanting medical devices - are much more likely to recover and have lower chances of dying, according to new research by the Zeenat Qureshi Stroke Research Center at the University of Minnesota Medical School.
(more…)
Tags: Abnormal Blood, Blood Clots, Drugs, Dual Treatment, Endovascular Interventions, Improved Recovery, Invasive Treatment, Medical Devices, Minnesota Medical School, Mortality, Stroke Patients, Stroke Research Center, Thrombolysis, University Of Minnesota, University Of Minnesota Medical, University Of Minnesota Medical School, Zeenat
17 Nov 08 Covered Stent Use Minimized By European Health Care Reforms, According To Millennium Research Group
According to Millennium Research Group’s (MRG’s) Europe II Markets for Peripheral Vascular Devices report, covering Spain, Switzerland, Benelux, and Nordic countries, health care reforms have limited the adoption of covered stents in peripheral vascular applications.
(more…)
17 Nov 08 Covered Stent Use Minimized By European Health Care Reforms, According To Millennium Research Group
According to Millennium Research Group’s (MRG’s) Europe II Markets for Peripheral Vascular Devices report, covering Spain, Switzerland, Benelux, and Nordic countries, health care reforms have limited the adoption of covered stents in peripheral vascular applications.
(more…)
17 Nov 08 Covered Stent Use Minimized By European Health Care Reforms, According To Millennium Research Group
According to Millennium Research Group’s (MRG’s) Europe II Markets for Peripheral Vascular Devices report, covering Spain, Switzerland, Benelux, and Nordic countries, health care reforms have limited the adoption of covered stents in peripheral vascular applications.
(more…)
Tags: Adoption, Benelux, Europe, European Health Care, Health Care Reforms, Health Research, Limited, Millennium Group, Millennium Research Group, Mrg, Nordic Countries, Spain, Stents, Switzerland
17 Nov 08 Dronedarone (Multaq) Reduced The Incidence And Duration Of Hospitalization In Patients With Atrial Fibrillation
New data from the landmark ATHENA trial showed that dronedarone significantly reduced the incidence and total duration of hospital stays among patients with atrial fibrillation / atrial flutter (AF/AFL). This post-hoc analysis was presented at the American Heart Association Scientific Sessions 2008 in New Orleans, Louisiana. In this new analysis, dronedarone significantly reduced the total number of hospital days by 28 percent (p
(more…)
Tags: Afl, American Heart Association, American Heart Association Scientific Sessions, Athena, Atrial Fibrillation, Atrial Flutter, Duration, Hospitalization, Landmark, New Orleans Louisiana, Post Hoc Analysis
